Fixed-duration cytarabine consolidation improves relapse-free survival over indefinite AZA-VEN in younger AML.

Blood Cancer J · 2026 · PMC13083873 · PMID 41986325

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

In contrast, in the Aza-Ven continuation group, MRD negativity showed a trend toward improved RFS compared with MRD-positive disease (HR 0.27; 95% CI 0.07–1.08; p = 0.06), whereas age (HR 0.97; 95% CI 0.92–1.01; p = 0.08) and favourable ELN 2022 risk (HR 0.53; 95% CI 0.11–2.68; p = 0.30) were not significant predictors.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.